UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
UV1 is a therapeutic cancer vaccine that has been explored in prostate, lung cancer, in combination with ipilimumab in malignant melanoma and in combination with pembrolizumab in metastatic melanoma. This study will explore the Efficacy and Safety of UV1 administered with GM-CSF in combination with nivolumab and ipilimumab.
Efficacy and Safety of UV1 Vaccination in Combination With Nivolumab and Ipilimumab as First Line Treatment of Patients With Unresectable or Metastatic Melanoma (INITIUM Study)
This is a randomized, open label study to investigate efficacy and safety of UV1 vaccination in combination with nivolumab and ipilimumab as first line treatment of adult patients with histologically confirmed unresectable metastatic melanoma. Patients in the experimental arm will receive 8 UV1 vaccinations over 4 cycles of nivolumab and ipilimumab. Patients in the control arm will receive 4 cycles of nivolumab and ipilimumab. Patients in both arms will start maintenance therapy 6 weeks after the last dose of induction therapy, nivolumab at a dose of 480 mg every 4 weeks. All patients will be followed up until death or until the end of the study.
Malignant Melanoma Melanoma Nivolumab Ipilimumab Sargramostim UV1 vaccination + nivolumab and ipilimumab Nivolumab and ipilimumab
You can join if…
Open to people ages 18 years and up
- Male or female patients at least 18 years of age at the time of signing the ICF.
- Histologically confirmed diagnosis of unresectable stage IIIB D, or unresectable stage IV malignant melanoma.
- Eligible for combination treatment with nivolumab and ipilimumab.
- An ECOG performance status of 0 or 1.
- Adequate organ function as indicated by the following laboratory values:
- Absolute neutrophil count ≥1,500/µL
- Platelet count ≥100 x 103/µL
- Hemoglobin ≥9 g/dL or ≥5.6 mmol/L Renal
- Creatinine ≤1.5 x upper limit of normal (ULN) Hepatic
- Total bilirubin ≤1.5 x ULN or direct bilirubin ≤ ULN for patients with total bilirubin levels >1.5 ULN
- Aspartate aminotransferase/serum glutamic oxaloacetic transaminase and alanine aminotransferase/serum glutamic pyruvic transaminase ≤2.5 x ULN for patients without liver metastasis or ≤5 x ULN for patients with liver metastasis.
- Male patients who are sexually active with a female of childbearing potential must agree to use an adequate method of contraception.
- Women of childbearing potential (WOCBP) must have a negative urine or serum/plasma pregnancy test.
- WOCBP must use adequate contraception.
You CAN'T join if...
- Previous non melanoma malignancies unless curatively treated and complete remission was achieved at least 2 years prior to randomization. Patients with prior curatively treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or carcinoma in situ of the breast, or other in situ cancers are allowed irrespective of time passed since curative treatment. Patients with prior completely resected malignant melanoma are also allowed.
- Known brain metastases or leptomeningeal metastases. If a patient experiences neurological symptoms indicative of brain metastases, a brain MRI should be performed.
- Diagnosis of uveal or ocular melanoma.
- Known history or any evidence of active, non-infectious pneumonitis.
- History of New York Heart Association class 3-4 congestive heart failure or history of myocardial infarction within 6 months of starting induction therapy.
- Active infection requiring systemic treatment.
- Diagnosis of immunodeficiency.
- Known history of severe hypersensitivity reactions to nivolumab, ipilimumab, sargramostim, or their excipients.
- Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).
- . History of or active hepatitis B (hepatitis B surface antigen reactive) or active hepatitis C (hepatitis C virus antibody).
- . Women who are breastfeeding.
- . Prior systemic treatment for unresectable stage IIIB D or unresectable stage IV malignant melanoma.
- . Systemic corticosteroid treatment (doses exceeding 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive treatment within 7 days prior to the first dose of induction therapy.
- . Receipt of a live vaccine within 30 days prior to start of induction therapy.
- . Receipt of any other investigational treatment within 4 weeks of the first dose of induction therapy.
- University of California Irvine Health
accepting new patients
Orange California 92868 United States
- Saint John's Health Center - John Wayne Cancer Institute (JWCI)
accepting new patients
Santa Monica California 90404 United States
- accepting new patients
- Start Date
- Completion Date
- Ultimovacs ASA
- Phase 2 research study
- Study Type
- Expecting 154 study participants
- Last Updated
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
The study team should get back to you in a few business days.